Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLDX 
Celldex Therapeutics Inc (CLDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CLDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $55.62
1 Year Target Price $55.62
| 10 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.19% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.49B USD | Price to earnings Ratio - | 1Y Target Price 55.62 |
Price to earnings Ratio - | 1Y Target Price 55.62 | ||
Volume (30-day avg) 14 | Beta 1.22 | 52 Weeks Range 14.40 - 47.00 | Updated Date 08/28/2025 |
52 Weeks Range 14.40 - 47.00 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.86 | Actual -0.85 |
Profitability
Profit Margin - | Operating Margin (TTM) -8747.53% |
Management Effectiveness
Return on Assets (TTM) -19.08% | Return on Equity (TTM) -27.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 858872454 | Price to Sales(TTM) 256.68 |
Enterprise Value 858872454 | Price to Sales(TTM) 256.68 | ||
Enterprise Value to Revenue 148.34 | Enterprise Value to EBITDA -17.34 | Shares Outstanding 66406500 | Shares Floating 53206915 |
Shares Outstanding 66406500 | Shares Floating 53206915 | ||
Percent Insiders 0.19 | Percent Institutions 111.32 |
Upturn AI SWOT
Celldex Therapeutics Inc
Company Overview
History and Background
Celldex Therapeutics Inc. was founded in 1991. Originally focused on antibody discovery, it has evolved into a biopharmaceutical company developing targeted therapeutics to treat cancer and other diseases. The company has faced setbacks and shifted its focus over time.
Core Business Areas
- Oncology Therapeutics Development: Focuses on developing antibody-based therapeutics for various cancer types. This includes pipeline products targeting specific cancer cell surface markers.
Leadership and Structure
Anthony Marucci is the Co-founder, President and CEO. The company has a board of directors and a management team responsible for overseeing various departments like research, development, and finance.
Top Products and Market Share
Key Offerings
- Varlilumab (CDX-1127): An investigational fully-human CD27 agonist antibody. It's in clinical development for various cancers, often in combination with other therapies. Market share data is not yet applicable as it is not approved yet. Competitors in the immuno-oncology space include Bristol Myers Squibb (BMY), Merck (MRK), and Roche (RHHBY).
- CDX-0159: An investigational anti-KIT monoclonal antibody. It's in clinical development for chronic inducible urticaria (CIU). Market share data is not yet applicable as it is not approved yet. Competitors in the Urticaria therapeutic market include Novartis (NVS) and Genentech.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory scrutiny. Immuno-oncology and targeted therapies are growing segments.
Positioning
Celldex Therapeutics focuses on novel antibody-based therapies, differentiating through targeting specific pathways and combination strategies. Its competitive advantage lies in its unique targets and antibody engineering expertise.
Total Addressable Market (TAM)
The overall oncology drug market is estimated to reach hundreds of billions of dollars. Celldex Therapeutics targets specific niches within this market, with TAM dependent on the success of its individual pipeline assets.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Experienced management team
- Strong antibody engineering capabilities
- Proprietary technology platforms
Weaknesses
- Dependence on pipeline success
- Limited revenue stream
- High R&D expenses
- Susceptibility to clinical trial failures
Opportunities
- Strategic partnerships
- Expansion into new indications
- Advancements in immuno-oncology
- Increased funding for cancer research
Threats
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Patent expiration
Competitors and Market Share
Key Competitors
- BMY
- MRK
- NVS
- RHHBY
- LLY
- REGN
Competitive Landscape
Celldex Therapeutics competes with larger pharmaceutical companies with more resources. Its success depends on the differentiation and clinical efficacy of its novel therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on clinical trial successes and potential partnerships. The company has experienced periods of significant stock price volatility based on news flow.
Future Projections: Future growth is tied to the success of its pipeline assets. Analyst estimates vary based on clinical trial outcomes and market potential.
Recent Initiatives: Focus on advancing CDX-0159 in CIU and Varlilumab in combination therapies. Expanding clinical trials and seeking strategic partnerships.
Summary
Celldex Therapeutics is a clinical-stage biopharmaceutical company relying on pipeline success. Strengths include novel targets, offset by limited revenue. Advancing CDX-0159 and Varlilumab is key. Competitors are larger and more established, so clinical trials and strategic partnerships are essential for success. Watch for upcoming trial results and any collaborations or partnering of their treatments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Celldex Therapeutics Investor Relations
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated based on available information. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celldex Therapeutics Inc
Exchange NASDAQ | Headquaters Hampton, NJ, United States | ||
IPO Launch date 2008-03-10 | Founder, President, CEO & Director Mr. Anthony S. Marucci M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 186 | Website https://www.celldex.com |
Full time employees 186 | Website https://www.celldex.com | ||
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.